Advertisement

Mammakarzinom pp 125-136 | Cite as

Operative Taktik und Technik nach Präoperativer Chemotherapie

  • E. Sporn
  • M. Gnant
Chapter
  • 813 Downloads

Auszug

Die Durchführung einer präoperativen systemischen Chemotherapie (PST) stellt heute einen wichtigen Eckpfeiler in der multimodalen Therapie des fortgeschrittenen Mammakarzinoms dar. Dadurch wird eine Brusterhaltung in Behandlungssituationen, die früher eine Mastekomie erforderlich gemacht hätten, bei einem Teil der Patientinnen möglich. Allerdings stellt die Behandlung von Patientinnen, die mit einer präoperativen Chemotherapie vorbehandelt wurden, in Operationsplanung und -durchführung besondere Anforderungen an den behandelnden Chirurgen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Abraham DC, Jones RC, Jones SE et al. (1996) Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imaging. Cancer 78: 91–100PubMedCrossRefGoogle Scholar
  2. Avril A, Faucher A, Bussieres E et al. (1998) Results of 10 years of a randomized trial of neoadjuvant chemotherapy in breast cancers larger than 3 cm. Chirurgie 123: 247–256PubMedCrossRefGoogle Scholar
  3. Bonadonna G (1992) Evolving concepts in the systemic adjuvant treatment of breast cancer. Cancer Res 52: 2127–2137PubMedGoogle Scholar
  4. Bonadonna G, Brusamolino E, Valagussa P et al. (1976) Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294: 405–410PubMedCrossRefGoogle Scholar
  5. Bonadonna G, Veronesi U, Brambilla C et al. (1990) Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 82: 1539–1545PubMedCrossRefGoogle Scholar
  6. Bonadonna G, Valagussa P, Brambilla C et al. (1998) Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol 16: 93–100PubMedGoogle Scholar
  7. Broadwater JR, Edwards MJ, Kuglen C, Hortobagyi GN, Ames FC, Balch CM (1991) Mastectomy following preoperative chemotherapy. Strict operative criteria control operative morbidity. Ann Surg 213: 126–129PubMedCrossRefGoogle Scholar
  8. Broet P, Scholl SM, de la Rochefordiere A et al. (1999) Short and long-term effects on survival in breast cancer patients treated by primary chemotherapy: an updated analysis of a randomized trial. Breast Cancer Res Treat 58: 151–156PubMedCrossRefGoogle Scholar
  9. Buzdar AU, Singletary SE, Booser DJ, Frye DK, Wasaff B, Hortobagyi GN (1995) Combined modality treatment of stage III and inflammatory breast cancer. M.D. Anderson Cancer Center Experience. Surg Oncol Clin North Am 4: 715–734Google Scholar
  10. Danforth DN Jr, Cowan K, Altemus R et al. (2003) Preoperative FLAC/granulocyte-colony-stimulating factor chemotherapy for stage II breast cancer: a prospective randomized trial. Ann Surg Oncol 10: 635–644PubMedCrossRefGoogle Scholar
  11. Early Breast Cancer Trialists’ Collaborative Group (1996) Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet 348(9036): 1189–1196CrossRefGoogle Scholar
  12. Early Breast Cancer Trialists’ Collaborative Group (1998 a) Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352(9132): 930–942CrossRefGoogle Scholar
  13. Early Breast Cancer Trialists’ Collaborative Group (1998 b) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351(9114): 1451–1467CrossRefGoogle Scholar
  14. Esserman L, Hylton N, Yassa L, Barclay J, Frankel S, Sickles E (1999) Utility of magnetic resonance imaging in the management of breast cancer: evidence for improved preoperative staging. J Clin Oncol 17: 110–119PubMedGoogle Scholar
  15. Fisher B, Carbone P, Economou SG et al. (1975) 1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings. N Engl J Med 292: 117–122PubMedCrossRefGoogle Scholar
  16. Fisher B, Gunduz N, Saffer EA (1983) Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. Cancer Res 43: 1488–1492PubMedGoogle Scholar
  17. Fisher B, Bauer M, Margolese R et al. (1985) Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med 312: 665–673PubMedCrossRefGoogle Scholar
  18. Fisher B, Redmond C, Poisson R et al. (1989) Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 320: 822–828PubMedCrossRefGoogle Scholar
  19. Fisher B, Brown A, Mamounas E et al. (1997) Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15: 2483–2493PubMedGoogle Scholar
  20. Fisher B, Bryant J, Wolmark N et al. (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16: 2672–2685PubMedGoogle Scholar
  21. Gazet JC, Ford HT, Gray R et al. (2001) Estrogen-receptor-directed neoadjuvant therapy for breast cancer: results of a randomised trial using formestane and methotrexate, mitozantrone and mitomycin C (MMM) chemotherapy. Ann Oncol 12: 685–691PubMedCrossRefGoogle Scholar
  22. Gianni L, Baselga J, Eiermann W et al. (2002) First report of the European Cooperative Trial in Operable Breast Cancer (ECTO): Effects of primary systemic therapy (PST) on local-regional disease. Proc Am Soc Clin Oncol 21: abstract 132Google Scholar
  23. Götzinger P, Gebhard B, Gnant M, Rudas M, Reiner A, Jakesz R (1998) Die Wertigkeit der Stanzbiopsie in der Diagnostik palpabler Brusttumoren: eine prospektive Analyse von 150 Patienten. Chirurg 69: 1068–1071PubMedCrossRefGoogle Scholar
  24. Gunduz N, Fisher B, Saffer EA (1979) Effect of surgical removal on the growth and kinetics of residual tumor. Cancer Res 39: 3861–3865PubMedGoogle Scholar
  25. Hortobagyi GN (1997) Anthracyclines in the treatment of cancer. An overview. Drugs 54(Suppl 4): 1–7PubMedCrossRefGoogle Scholar
  26. Hortobagyi GN, Blumenschein GR, Spanos W et al. (1983) Multimodal treatment of locoregionally advanced breast cancer. Cancer 51: 763–768PubMedCrossRefGoogle Scholar
  27. Hortobagyi GN, Ames FC, Buzdar AU et al. (1988) Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 62: 2507–2516PubMedCrossRefGoogle Scholar
  28. Jacquillat C, Weil M, Baillet F et al. (1990) Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer. Cancer 66: 119–129PubMedCrossRefGoogle Scholar
  29. Jakesz R for the ABCSG (2001) Comparison of pre-vs. postoperative chemotherapy in breast cancer patients: four-year results of Austrian Breast and Colorectal Cancer Study Group (ABCSG) Trial 7. Proc Am Soc Clin Oncol 20: abstract 125Google Scholar
  30. Kaufmann M, Minckwitz G v, Smith R et al. (2003) International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol 21: 2600–2608PubMedCrossRefGoogle Scholar
  31. Kuerer HM, Newman LA, Buzdar AU et al. (1998 a) Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status. Cancer J Sci Am 4: 230–236PubMedGoogle Scholar
  32. Kuerer HM, Newman LA, Buzdar AU et al. (1998 b) Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. Am J Surg 176: 502–509PubMedCrossRefGoogle Scholar
  33. Kuerer HM, Newman LA, Smith TL et al. (1999) Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17: 460–469PubMedGoogle Scholar
  34. Kuerer HM, Singletary SE, Buzdar AU et al. (2001) Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma. Am J Surg 182: 601–608PubMedCrossRefGoogle Scholar
  35. Lawrence WT, Norton JA, Harvey AK, Gorschboth CM, Talbot TL, Grotendorst GR (1986) Doxorubicin-induced impairment of wound healing in rats. J Natl Cancer Inst 76: 119–126PubMedGoogle Scholar
  36. Makris A, Powles TJ, Ashley SE et al. (1998) A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol 9: 1179–1184PubMedCrossRefGoogle Scholar
  37. Mamounas EP, Brown A, Anderson S et al. (2005) Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 23: 2694–2702PubMedCrossRefGoogle Scholar
  38. Margolese RG (1998) Surgical considerations in preoperative chemotherapy of breast cancer. Recent Results Cancer Res 152: 193–201PubMedGoogle Scholar
  39. Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst (2005; 97(3): 188–94.PubMedCrossRefGoogle Scholar
  40. Mauriac L, Durand M, Avril A, Dilhuydy JM (1991) Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre. Ann Oncol 2: 347–354PubMedGoogle Scholar
  41. Mauriac L, MacGrogan G, Avril A et al. (1999) Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol 10: 47–52PubMedCrossRefGoogle Scholar
  42. Minckwitz G v, Blohmer JU, Raab G et al. (2005 a) In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. Ann Oncol 16: 56–63CrossRefGoogle Scholar
  43. Minckwitz G v, Raab G, Caputo A et al. (2005 b) Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol 23: 2676–2685CrossRefGoogle Scholar
  44. Newman LA, Buzdar AU, Singletary SE et al. (2002) A prospective trial of preoperative chemotherapy in resectable breast cancer: predictors of breast-conservation therapy feasibility. Ann Surg Oncol 9: 228–234PubMedGoogle Scholar
  45. Nystrom L, Andersson I, Bjurstam N, Frisell J, Nordenskjold B, Rutqvist LE (2002) Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet 359(9310): 909–919PubMedCrossRefGoogle Scholar
  46. O’Reilly MS, Boehm T, Shing Y et al. (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277–285PubMedCrossRefGoogle Scholar
  47. Rouzier R, Extra JM, Carton M et al. (2001) Primary chemotherapy for operable breast cancer: incidence and prognostic significance of ipsilateral breast tumor recurrence after breast-conserving surgery. J Clin Oncol 19: 3828–3835PubMedGoogle Scholar
  48. Scholl SM, Asselain B, Palangie T et al. (1991) Neoadjuvant chemotherapy in operable breast cancer. Eur J Cancer 27: 1668–1671PubMedCrossRefGoogle Scholar
  49. Scholl SM, Fourquet A, Asselain B et al. (1994) Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer 30A: 645–652PubMedCrossRefGoogle Scholar
  50. Schwartz GF, Hortobagyi GN, Masood S, Palazzo J, Holland R, Page D (2004) Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26–28, 2003, Philadelphia, PA. Hum Pathol 35: 781–784PubMedCrossRefGoogle Scholar
  51. Semiglazov VF, Topuzov EE, Bavli JL et al. (1994) Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb–IIIa breast cancer. Ann Oncol 5: 591–595PubMedGoogle Scholar
  52. Shin HJ, Sneige N (1998) Is a diagnosis of infiltrating versus in situ ductal carcinoma of the breast possible in fine-needle aspiration specimens? Cancer 84: 186–191PubMedCrossRefGoogle Scholar
  53. Smith RA, Saslow D, Sawyer KA et al. (2003) American Cancer Society guidelines for breast cancer screening: update 2003. CA Cancer J Clin 53: 141–169PubMedGoogle Scholar
  54. Steger GG, Kubista E, Hausmanninger H (2004) 6 vs. 3 cycles of epirubicine/docetaxel + G-CSF in operable breast cancer. J Clin Oncol 22: 553, abstract 15Google Scholar
  55. Valero V, Buzdar AU, McNeese M, Singletary E, Hortobagyi GN (2002) Primary chemotherapy in the treatment of breast cancer: the University of Texas M.D. Anderson Cancer Center Experience. Clin Breast Cancer 3(Suppl 2): S63–S68PubMedGoogle Scholar
  56. Van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L (2001) Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 19: 4224–4237PubMedGoogle Scholar
  57. Veronesi U, Saccozzi R, Del Vecchio M et al. (1981) Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. N Engl J Med 305: 6–11PubMedCrossRefGoogle Scholar
  58. Veronesi U, Banfi A, Salvadori B et al. (1990) Breast conservation is the treatment of choice in small breast cancer: long-term results of a randomized trial. Eur J Cancer 26: 668–670PubMedGoogle Scholar
  59. Veronesi U, Cascinelli N, Mariani L et al. (2002) Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 347: 1227–1232PubMedCrossRefGoogle Scholar
  60. Vinnicombe SJ, MacVicar AD, Guy RL et al. (1996) Primary breast cancer: mammographic changes after neoadjuvant chemotherapy, with pathologic correlation. Radiology 198: 333–340PubMedGoogle Scholar
  61. Warren RM, Bobrow LG, Earl HM et al. (2004) Can breast MRI help in the management of women with breast cancer treated by neoadjuvant chemotherapy? Br J Cancer 90: 1349–1360PubMedCrossRefGoogle Scholar
  62. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B (2001) Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 30: 96–102PubMedGoogle Scholar

Copyright information

© Springer-Verlag / Wien 2007

Authors and Affiliations

  • E. Sporn
    • 1
  • M. Gnant
    • 2
  1. 1.Brustambulanz AKH Wien, Universitätsklinik für ChirurgieMedizinische Universität WienWien
  2. 2.Universitätsklinik für ChirurgieMedizinische Universität WienWien

Personalised recommendations